**Core Concept**
Transdermal delivery systems are used for various medications, including antiparkinsonian drugs, to provide steady-state plasma concentrations and reduce side effects. This method allows for controlled release of the active ingredient through the skin, bypassing first-pass metabolism.

**Why the Correct Answer is Right**
Rotigotine is a non-ergoline dopamine agonist that acts as a partial agonist at D1, D2, D3, D4, and D5 receptors. Its transdermal patch formulation provides a steady release of the drug, mimicking the natural physiological fluctuations in dopamine levels. This helps to alleviate symptoms of Parkinson's disease, such as tremors, stiffness, and bradykinesia. The transdermal patch formulation of rotigotine also allows for once-daily dosing, improving patient compliance and reducing the risk of side effects.

**Why Each Wrong Option is Incorrect**
**Option A:** Levodopa is a precursor to dopamine, which is converted to dopamine by dopa-decarboxylase in the brain. It is typically administered orally, not transdermally, and requires carbidopa as a decarboxylase inhibitor to prevent peripheral conversion.
**Option B:** Pramipexole is an ergoline-derived dopamine agonist that is available in oral and sublingual formulations, but not as a transdermal patch.
**Option C:** Apomorphine is an ergoline-derived dopamine agonist that is used as an injectable rescue medication for severe Parkinson's disease symptoms, but not as a transdermal patch.

**Clinical Pearl / High-Yield Fact**
Rotigotine's transdermal patch formulation is a good option for patients who experience fluctuations in levodopa response or have difficulty with oral medications. It is essential to counsel patients on proper patch application and rotation to maintain therapeutic efficacy.

**Correct Answer:** C. Apomorphine is an ergoline-derived dopamine agonist that is used as an injectable rescue medication for severe Parkinson's disease symptoms, but not as a transdermal patch